readthroughSign in
Oct 19, 2026Clinical readoutUpdated

Alector schedules R&D webinar on wholly owned pipeline after Genentech GCase deal

Alector plans an October 13 webinar on its anti-Abeta, tau, and alpha-synuclein programs following its $100 million upfront Genentech license and updated cash guidance into 2029.

Alector, Inc. said it will host a scientific webinar on Tuesday, October 13th, 2026, at 8:00 a.m. PT, focused on AL137, its brain-enabled anti-Aβ antibody; AL164, its tau siRNA program; and AL062, its alpha-synuclein siRNA program, with registration and webcast information to be available on the Events and Presentations page of the Alector corporate website.1

The planned event follows a license agreement the company signed on September 30, 2026. Under that deal, Alector is granting Genentech exclusive worldwide rights to develop and commercialize Alector's AL050 program, a brain penetrant engineered glucocerebrosidase enzyme replacement therapy.1 Genentech will be responsible for development, regulatory, manufacturing, and commercialization of the GCase Candidates, and Alector will assign ownership of certain of its existing patents specific to the GCase Candidates to Genentech.1 Alector retains ownership of its Alector Brain Carrier platform and full rights to apply the platform across its wholly owned pipeline of compound and product candidates outside of GCases.1

Financially, Alector will receive a $100 million upfront payment from Genentech, is eligible to receive up to an additional $1.17 billion in development, regulatory, and commercial success-related milestone payments, and will be eligible for tiered royalties on a specified percentage of net sales at rates ranging from single-digit to double-digit percentages.1

CEO Arnon Rosenthal said the partnership extends the company's cash runway into 2029, providing resources to advance its fully active, subcutaneously delivered, brain-enabled anti-Aβ antibody to multi-cohort clinical data in Alzheimer's patients, and move its subcutaneously delivered, brain-enabled Tau siRNA and alpha-synuclein siRNA programs through IND-enabling studies and to IND filings.1

On cash, the company said cash, cash equivalents, and marketable securities totaled approximately $138.7 million as of September 30, 2026, and Alector would have approximately $223.7 million of cash, cash equivalents, and marketable securities as of September 30, 2026 after giving pro forma effect to the initial payments received under the Genentech License Agreement and paid out under the Spur Agreement, which the Company believes will enable it to fund its operations into 2029.1 The company noted it has not yet completed its quarter-end financial close processes for the quarter ended September 30, 2026, and the estimate is preliminary, has not been audited, and is subject to change.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.